Local treatment with recombinant tissue factor pathway inhibitor reduces the development of intimal hyperplasia in experimental vein grafts.
BACKGROUND
Tissue factor (TF)-initiated thrombin generation has been implicated in the development of intimal hyperplasia after arterial injury. An increase in intimal TF expression has been shown to precede the development of intimal hyperplasia in vein grafts. This study examines the effects of local treatment with recombinant human tissue factor pathway inhibitor (rTFPI) in experimental vein grafts.


METHODS
Thirty-six male New Zealand white rabbits underwent bypass grafting of the carotid artery by use of the reversed ipsilateral jugular vein and were divided into four groups. Twenty animals had ex vivo incubation with rTFPI treatment (50 microg x mL(-1); n = 10) or placebo vehicle (control; n = 10). Sixteen animals received both ex vivo incubation and in vivo gel treatment with rTFPI (50 microg. mL(-1); n = 8) or without rTFPI (gel-control; n = 8). After operation, vein grafts were harvested at 3 days for immunohistochemical and Western analyses and at 28 days for histomorphologic study.


RESULTS
Western analysis demonstrated a 6.2-fold reduction in the expression of TF protein with rTFPI treatment in comparison to without rTFPI treatment. CD-18 leukocyte staining was diminished, whereas Tie-2 endothelial staining was increased in all rTFPI-treated vein grafts, compared with control and gel-control vein grafts. Intimal thickness was reduced by 21% with ex vivo rTFPI treatment compared with placebo (69 +/- 4 versus 87 +/- 5 microm; P <.05) and by 30% with the addition of rTFPI in vivo compared with gel-control (60 +/- 4 versus 86 +/- 5 microm; P <.01).


CONCLUSIONS
Local administration of rTFPI exerts early beneficial effects and limits the development of intimal hyperplasia in vein grafts. Therefore blocking TF-mediated pathway may offer new therapeutic options to reduce vein graft failure.
Huynh
T T
TT
Department of Surgery, Duke University Medical Center and Durham VA Medical Center, NC, USA. tam.t.huynh@uth.tmc.edu
Davies
M G
MG
Thompson
M A
MA
Ezekowitz
M D
MD
Hagen
P
P
Annex
B H
BH
D000818:Animals; D000925:Anticoagulants / Q000494:pharmacology*; D015153:Blotting, Western; D018821:CD18 Antigens / Q000032:analysis; D002339:Carotid Arteries / Q000601:surgery; D006965:Hyperplasia; D007150:Immunohistochemistry; D066298:In Vitro Techniques; D007601:Jugular Veins / Q000473:pathology* / Q000637:transplantation*; D008074:Lipoproteins / Q000494:pharmacology*; D008297:Male; D011817:Rabbits; D011994:Recombinant Proteins / Q000494:pharmacology; D013925:Thromboplastin / Q000096:biosynthesis; D017539:Tunica Intima / Q000378:metabolism / Q000473:pathology*
D000925:Anticoagulants; D018821:CD18 Antigens; D008074:Lipoproteins; D011994:Recombinant Proteins; C051928:lipoprotein-associated coagulation inhibitor; D013925:Thromboplastin